HK Stock MarketDetailed Quotes

02256 ABBISKO-B

Watchlist
  • 2.880
  • +0.020+0.70%
Market Closed Mar 28 16:08 CST
2.02BMarket Cap-4247P/E (TTM)

About ABBISKO-B Company

We are an R&D-driven clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since inception, we have built a strong internal R&D engine, supported by our outstanding discovery team and multi-dimensional discovery platform. With strong discovery capabilities, we have strategically designed and developed more than 10 oncology-focused projects, including five in the clinical phase. We aspire to be a leading biopharmaceutical company to discover and develop novel differentiated therapies in cancer and other fields to meet the critical unmet needs of patients in China and around the world. We strategically focus on small molecule precision oncology therapy, small molecule immuno-oncology, and combination therapies. With their good efficacy and safety, we believe this is the development trend and next generation solution for cancer treatment.

Company Profile

Symbol02256
Company NameABBISKO-B
ISINKYG0028A1085
Listing Date10/13/2021
Issue Price12.46
Shares Offered140.74M share
Founded03/28/2018
RegistrationCayman Islands
ChairmanYaochang Xu
SecretaryHuimin\chenyanhua Tian
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeP.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Financial Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees252
MarketHong Kong motherboard
Phone(86021)68912098
EmailPublic@abbisko.com;Bd@abbisko.com
Business Heyu Cayman Co., Ltd. is a Chinese clinical-stage biopharmaceutical company. The company is dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has two core candidates, ABSK011 and ABSK091, and 12 other pipeline candidates. ABSK011 is an effective, highly selective small molecule fibroblast growth factor receptor 4 (FGFR4) inhibitor. ABSK091 is a molecularly targeted candidate product and is a highly effective and selective inhibitor of FGFR subtypes 1, 2, and 3. The company's products are mainly used to treat hepatocellular carcinoma (HCC), urothelial carcinoma (UC) and gastric cancer (GC).

Company Executives

  • Name
  • Position
  • Salary
  • Yaochang Xu
  • Chairman of the Board,Executive Director,Authorized Representative,CEO,Nomination Committee Chairman,Remuneration Committee Member
  • --
  • Hongping Yu
  • Senior Vice President of Medicinal Chemistry,Executive Director,Chief Scientific Officer
  • --
  • Chui Chen
  • Senior Vice President of Biology,Executive Director,Chief Scientific Officer
  • --
  • Yanmin Tang
  • Non-Executive Director
  • --
  • Piaoyang Sun
  • Independent Non-Executive Director,Nomination Committee Member,Audit Committee Member
  • --
  • Hongbin Sun
  • Nomination Committee Member,Audit Committee Chairman,Independent Non-Executive Director,Remuneration Committee Member
  • --
  • Lei Wang
  • Audit Committee Member,Remuneration Committee Chairman,Independent Non-Executive Director
  • --
  • Jing Ji
  • Chief Medical Officer
  • --
  • Zidong Zhang
  • CFO
  • --
  • Yongyi Li
  • General Counsel
  • --
  • Zhen Zhang
  • Head of Chemical, Manufacturing and Control (CMC),VP
  • --
  • Huimin Tian
  • Joint Company Secretary
  • --
  • Yanhua Chen
  • Authorized Representative,Joint Company Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg